Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Proof-of-Concept Study of Talacotuzumab or Daratumumab in ESA-Refractory Low/Int-1 Risk MDS
2016-003328-22Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in myelodysplastic syndrome (MDS) comparing Talacotuzumab arm with Daratumumab arm (2 arms). Primary endpoint: 8-week red blood cell transfusion independence. Started Dec 2016; status: completed.
02
Drugs
talacotuzumabdaratumumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2016-003328-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003328-22.